These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
442 related articles for article (PubMed ID: 20516378)
1. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Berger PB; Bhatt DL; Fuster V; Steg PG; Fox KA; Shao M; Brennan DM; Hacke W; Montalescot G; Steinhubl SR; Topol EJ; Circulation; 2010 Jun; 121(23):2575-83. PubMed ID: 20516378 [TBL] [Abstract][Full Text] [Related]
2. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Bhatt DL; Flather MD; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Fabry-Ribaudo L; Hu T; Topol EJ; Fox KA; J Am Coll Cardiol; 2007 May; 49(19):1982-8. PubMed ID: 17498584 [TBL] [Abstract][Full Text] [Related]
3. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Berger JS; Bhatt DL; Steg PG; Steinhubl SR; Montalescot G; Shao M; Hacke W; Fox KA; Berger PB; Topol EJ; Lincoff AM Am Heart J; 2011 Jul; 162(1):98-105.e1. PubMed ID: 21742095 [TBL] [Abstract][Full Text] [Related]
4. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Bhatt DL; Topol EJ; Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995 [TBL] [Abstract][Full Text] [Related]
5. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Mak KH; Bhatt DL; Shao M; Hankey GJ; Easton JD; Fox KA; Topol EJ Am Heart J; 2009 Apr; 157(4):658-65. PubMed ID: 19332192 [TBL] [Abstract][Full Text] [Related]
6. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Aronow HD; Steinhubl SR; Brennan DM; Berger PB; Topol EJ; Am Heart J; 2009 Feb; 157(2):369-74. PubMed ID: 19185647 [TBL] [Abstract][Full Text] [Related]
7. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Wang TH; Bhatt DL; Fox KA; Steinhubl SR; Brennan DM; Hacke W; Mak KH; Pearson TA; Boden WE; Steg PG; Flather MD; Montalescot G; Topol EJ; Eur Heart J; 2007 Sep; 28(18):2200-7. PubMed ID: 17673448 [TBL] [Abstract][Full Text] [Related]
8. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S; Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Dasgupta A; Steinhubl SR; Bhatt DL; Berger PB; Shao M; Mak KH; Fox KA; Montalescot G; Weber MA; Haffner SM; Dimas AP; Steg PG; Topol EJ; Am J Cardiol; 2009 May; 103(10):1359-63. PubMed ID: 19427428 [TBL] [Abstract][Full Text] [Related]
10. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889 [TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961 [TBL] [Abstract][Full Text] [Related]
12. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Hart RG; Bhatt DL; Hacke W; Fox KA; Hankey GJ; Berger PB; Hu T; Topol EJ; Cerebrovasc Dis; 2008; 25(4):344-7. PubMed ID: 18303254 [TBL] [Abstract][Full Text] [Related]
13. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. Yusuf S; Zhao F; Mehta SR; Chrolavicius S; Tognoni G; Fox KK; N Engl J Med; 2001 Aug; 345(7):494-502. PubMed ID: 11519503 [TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Welsh RC; Rao SV; Zeymer U; Thompson VP; Huber K; Kochman J; McClure MW; Gretler DD; Bhatt DL; Gibson CM; Angiolillo DJ; Gurbel PA; Berdan LG; Paynter G; Leonardi S; Madan M; French WJ; Harrington RA; Circ Cardiovasc Interv; 2012 Jun; 5(3):336-46. PubMed ID: 22647518 [TBL] [Abstract][Full Text] [Related]
15. The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Mak KH; Bhatt DL; Shao M; Haffner SM; Hamm CW; Hankey GJ; Johnston SC; Montalescot G; Steg PG; Steinhubl SR; Fox KA; Topol EJ Eur Heart J; 2009 Apr; 30(7):857-65. PubMed ID: 19233855 [TBL] [Abstract][Full Text] [Related]
16. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Gwon HC; Hahn JY; Park KW; Song YB; Chae IH; Lim DS; Han KR; Choi JH; Choi SH; Kang HJ; Koo BK; Ahn T; Yoon JH; Jeong MH; Hong TJ; Chung WY; Choi YJ; Hur SH; Kwon HM; Jeon DW; Kim BO; Park SH; Lee NH; Jeon HK; Jang Y; Kim HS Circulation; 2012 Jan; 125(3):505-13. PubMed ID: 22179532 [TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Best PJ; Steinhubl SR; Berger PB; Dasgupta A; Brennan DM; Szczech LA; Califf RM; Topol EJ; Am Heart J; 2008 Apr; 155(4):687-93. PubMed ID: 18371477 [TBL] [Abstract][Full Text] [Related]
18. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Bhatt DL; Fox KA; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Flather MD; Haffner SM; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Booth J; Topol EJ; Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169314 [TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. Cannon CP; Husted S; Harrington RA; Scirica BM; Emanuelsson H; Peters G; Storey RF; J Am Coll Cardiol; 2007 Nov; 50(19):1844-51. PubMed ID: 17980250 [TBL] [Abstract][Full Text] [Related]
20. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. Serebruany VL; Malinin AI; Pokov AN; Hanley DF Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]